Click here for international medical scientific information about Oncology for Healthcare Professionals.
Click here for general international information for patients, caregivers and the general public.
BI 765063: a SIRPα myeloid checkpoint inhibitor
BI 765063* is a first-in-class myeloid checkpoint inhibitor (ICI).1 By blocking the interaction between myeloid cell surface molecule signal-regulatory protein alpha (SIRPα) and cluster of differentiation 47 (CD47), SIRPα inhibits suppression of the innate immune system and restores the immune functions of myeloid cells in the tumour microenvironment.1,2
BI 765063 is currently undergoing investigation as a monotherapy and in combination with anti-programmed cell death protein-1 (PD-1) ICI in a Phase I trial involving patients with solid tumours.3
Role of SIRPα
Myeloid cells are an important immune cell type in many solid tumours and their presence in a tumour is often associated with poor prognosis.4 Members of the SIRP family are mainly expressed on the surface of myeloid cells and contribute to the complex interaction between membrane proteins and leukocytes that regulate the body’s innate immune response.2,4
SIRPα is an inhibitory member of the SIRP family that binds to the receptor CD47. CD47 is highly expressed in many different types of cancer and transduces inhibitory signals through SIRPα on macrophages and other myeloid cells.2,5 The SIRPα/CD47 axis is a critical regulator of myeloid cell activation and serves as a myeloid-specific immune checkpoint.5
BI 765063’s mechanism of action
The interaction of SIRPα with CD47 contributes to immune-suppression in the tumour microenvironment by inhibiting phagocytosis of tumour cells, downregulation of antigen-presenting cells and maintenance of myeloid-derived suppressor cells.1,4 BI 765063 blocks the interaction of SIRPα with CD47, thereby restoring the immune functions of myeloid cells in the tumour microenvironment.1
Owing to its mechanism of action, BI 765063 may have particular clinical potential in solid tumours with higher myeloid cell infiltration (e.g. non-small cell lung cancer, colorectal cancer).6
Preclinical studies in murine tumour models have demonstrated the clinical benefit of SIRPα antagonist monotherapy, but suggest clinical outcomes may be enhanced through combination therapy with an adaptive PD-1 ICI, or with a costimulatory agent (such as anti-4-1BB monoclonal antibody), to provide dual activation of innate and acquired immunity.4,5
SIRPα myeloid checkpoint inhibitor mechanism of action
SIRPα, signal-regulatory protein alpha; CD47, cluster of differentiation.
BI 765063 is currently undergoing investigation as a monotherapy and in combination with PD-1 blockade in a Phase I trial involving patients with solid tumours.3
SIRPα, signal-regulatory protein alpha.
Boehringer Ingelheim. Data on file,
Barclay AN, et al. Nat Rev Immunol 2006;6(6):457–64
ClinicalTrials.gov. NCT TBC. http://clinicaltrials.gov/ct2/show/NCTTBC (Accessed: March 2019).
Gauttier V, et al. Cancer Res 2018;78(13 Suppl.): Abstract 1684.
Weiskopf K. Eur J Cancer 2017;76:100–9.
Cotechini T, et al. Cancer J. 2015;21:343–50.
*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.
© 2019 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: June 2019
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue